IDEXX Laboratories Inc

NASDAQ IDXX

Data sourced from

and

Download Data

IDEXX Laboratories Inc Net Working Capital to Total Assets Ratio 3 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: -2.57%

IDEXX Laboratories Inc Net Working Capital to Total Assets Ratio 3 year CAGR is -2.57% for the Trailing 12 Months (TTM) ending March 31, 2024. The net working capital to total assets ratio measures the proportion of a company's net working capital (current assets minus current liabilities) to its total assets. It is calculated by dividing the net working capital by the total assets. This ratio indicates the percentage of a company's total assets that are financed by its net working capital. A higher ratio suggests a greater reliance on working capital to fund the company's operations and indicates a potential liquidity cushion. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

IDEXX Laboratories Inc Net Working Capital to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was -0.03, a -129.27% change year over year.
IDEXX Laboratories Inc Net Working Capital to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.10, a -43.55% change year over year.
IDEXX Laboratories Inc Net Working Capital to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.18, a 10,183.69% change year over year.
IDEXX Laboratories Inc Net Working Capital to Total Assets Ratio for the Trailing 12 Months (TTM) ending March 31, 2020 was 0.00, a 105.28% change year over year.

NASDAQ: IDXX

IDEXX Laboratories Inc

CEO	Mr. Jonathan J. Mazelsky
IPO Date	June 21, 1991
Location	United States
Headquarters	One IDEXX Drive, Westbrook, ME, United States, 04092
Employees	11,000
Sector	Healthcare
Industry	Diagnostics & research

Description

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Key trends